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Abstract
Objective—The lymphatic vasculature is a well-established conduit for metastasis, but the 
mechanisms by which tumor cells interact with lymphatic endothelial cells (LECs) to facilitate 
escape remain poorly understood. Elevated levels of the lymphangiogenic peptide adrenomedullin 
(AM) are found in many tumors and we previously characterized that its expression is necessary 
for lymphatic vessel growth within both tumors and sentinel lymph nodes and for distant 
metastasis.
Approach and Results—This study used a tumor cell-LEC co-culture system to identify a 
series of AM-induced events that facilitated transendothelial migration (TEM) of the tumor cells 
through a lymphatic monolayer. High levels of AM expression enhanced adhesion of tumor cells 
to LECs and further analysis revealed that AM promoted gap junction coupling between LECs as 
evidenced by spread of Lucifer yellow dye. AM also enhanced heterocellular gap junction 
coupling as demonstrated by Calcein dye transfer from tumor cells into LECs. This connexin-
mediated gap junction intercellular communication (GJIC) was necessary for tumor cells to 
undergo TEM since pharmacological blockade of this heterocellular communication prevented the 
ability of tumor cells to transmigrate through the lymphatic monolayer. Additionally, treatment of 
LECs with AM caused nuclear translocation of β-catenin, a component of endothelial cell 
junctions, causing an increase in transcription of the downstream target gene C-MYC. Importantly, 
blockade of GJIC prevented β-catenin nuclear translocation.
Conclusions—Our findings indicate that maintenance of cell-cell communication is necessary 
to facilitate a cascade of events that lead to tumor cell migration through the lymphatic 
endothelium.
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Lymphatic vessels serve as a conduit by which tumor cells can escape to colonize distant 
organs. Seminal studies implicating the lymphangiogenic growth factors VEGF-C and 
VEGF-D in promoting tumor metastasis through enhanced lymphangiogenesis have 
provided insight into how lymphatics promote cancer progression 1-3. For example, VEGF-
C was shown to activate the lymphatic endothelium leading to vessel destabilization and 
thereby enabling tumor cell entry into the lymphatic vessel 4. In addition to VEGF family 
members, other processes such as chemoattraction 5, lymph flow 5, 6, enhanced adhesion 7, 
and lymph node lymphangiogenesis 8, 9 are also implicated in promoting entry of tumor 
cells into the lymphatic vasculature and facilitating metastasis. However, the precise 
mechanisms of how this occurs at the critical interface between the tumor cells and 
lymphatic endothelial cells (LECs) remains to be elucidated.
One mechanism by which neighboring cells interact to communicate and exchange 
information is through the formation of gap junction channels. Oligomerized connexin 
hexamers termed connexons from juxtaposed cells form channels that allow for cytoplasmic 
exchange of small signaling molecules such as metabolites, ions, and secondary messengers. 
Establishment of gap junctional intercellular communication (GJIC) through these channels 
is critical to maintain homeostasis during development and in adulthood 10. Of particular 
relevance, proper development of the lymphatic vasculature, specifically the lymphatic 
valves, is dependent on precise regulation and expression of certain members of the 
connexin protein family such as connexins (Cx) 37, and Cx43 11. In fact, missense 
mutations in the gap junction gene GJC2 (encoding Cx47) have been identified in families 
with dominantly inherited lymphedema 12. This finding is significant because it links 
impaired lymphatic activity with a mutation that alters gap junction function. These defects 
emphasize the critical role that connexins play in lymphatic function and disease 13.
Connexins appear to play diverse roles in cancer. Some studies suggest that expression of 
connexins confers a tumor suppressor function 14-16. Along these lines, mice heterozygous 
for Cx43 (Cx43+/−) had an increased susceptibility to urethane-induced lung tumors 17. 
More recent evidence, however, proposes that connexins are dynamically regulated 
depending on the stage of tumorigenesis, and therefore elevated levels may be important in 
promoting angiogenesis 18 and invasion 19-24. These data suggest that increased connexin 
expression in later stages of tumorigenesis enables tumor cells to penetrate the vessels and 
thus promote colonization of distant tissues. Moreover, connexin proteins also have channel-
independent functions 25 such as serving as adhesion sites which can mediate the invasion of 
glioma cells through the parenchyma 26.
Building upon our previous study which identified adrenomedullin (AM) as a factor which 
promotes tumor lymphangiogenesis and distant metastasis 27, we investigated the role of 
GJIC in this process. By focusing on the tumor cell – endothelial cell interactions, we 
identified a series of AM-induced events that promote the transendothelial migration of 
tumor cells including functional GJIC and subsequent β-catenin nuclear translocation. To 
our knowledge, this is the first study to detail how tumor cells and LECs physically interact 
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to facilitate tumor spread through the lymphatics. This study reinforces the often overlooked 
role that the lymphatic endothelium plays in actively promoting the metastatic process.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results
AM promotes the adhesion of tumor cells to the lymphatic endothelium and enhances 
their transendothelial migration
To test whether AM is involved in mediating adhesion of tumor cells to the lymphatic 
vasculature, we utilized AM-dosed LLC murine tumor cells that either express a 2-fold 
increase in Adm expression (AM OExp), a 92% reduction in Adm expression (AM RNAi) or 
maintain basal levels (EV; empty vector control) 27. Importantly, the LLC tumor cells have 
negligible expression of the AM receptor Calcrl 27, therefore the tumor cells are insensitive 
to manipulation of their AM levels since the AM-induced signal cannot be transduced 
through CLR. Rather, any resultant biological effects due to low or elevated AM levels can 
be attributed to AM-mediated signaling in other cell types in the microenvironment, such as 
LECs which express abundant CLR. The genetically AM-dosed cells were labeled with Cell 
Tracker Green (CTG) dye and added to an LEC monolayer. After 15 minutes of co-culture, 
fluorescence intensity was measured and we detected an AM dose dependent increase in the 
adhesion of tumor cells to the lymphatic monolayer (Figure 1A,B). We confirmed equal 
CTG fluorescence to ensure that altering Adm dosage does not affect CTG dye labeling 
(Figure 1C). Next, we utilized a pharmacologic approach to confirm that AM was mediating 
this adhesion. We treated the LEC monolayer with 1nM murine AM (mAM) peptide and the 
AM receptor antagonist AM22-52 and then added CTG-labeled LLC cells. Again, there was 
increased adhesion of tumor cells to LECs in the presence of AM and this adhesion was 
dramatically reduced in the presence of the AM inhibitor (Figure 1D). To corroborate these 
results, we analyzed the CTG-labeled human tumor cell line MCF-7 (Figure 1E) and 
similarly found that stimulation of LECs with 10nM human AM (hAM) peptide promoted 
the adhesion of the MCF-7 cells to the LECs (Figure 1F).
We then wanted to determine whether the AM-induced increase in tumor cell-LEC adhesion 
consequently results in enhanced transendothelial migration (TEM). Using a standard 
transwell assay, CTG-labeled AM-dosed tumor cells were added to transwell inserts which 
contained a confluent monolayer of LECs. Confluency was verified by H&E stained filters 
(data not shown). After 6 hours of co-culture, the filters from the inserts were removed and 
the fluorescent threshold area was determined. There was a significant increase in 
fluorescence as tumor derived AM dose increased, indicative of transmigrated CTG-labeled 
tumor cells (Figure 1G). To confirm that AM was responsible for the increased TEM, we 
repeated this experiment using a pharmacological approach. First we pre-treated the LEC 
monolayer with the AM inhibitor AM22-52 followed by addition of 10nM human or 1nM 
murine AM peptide. After the LEC monolayer was treated with AM for 5 minutes, CTG-
labeled murine LLC tumor cells or human MCF-7 and SK-MEL-2 tumor cells were added to 
the transwell inserts. Again, we observed an AM-induced increase in TEM in all 3 tumor 
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lines and the AM inhibitor reduced the transmigration to levels comparable to vehicle 
treatment (Figure 1H-J). Interestingly, the time course of TEM of the 2 human cells lines 
ranges from 3 to 24 hours for the SK-MEL-2 and MCF-7 cells, respectively. These data 
concur with the characterization that SK-MEL-2 cells are a highly metastatic cell line 
whereas the MCF-7 cells are reported to be weakly metastatic. In both instances, however, 
treatment with AM promotes TEM. Importantly, comparable to the LLC tumor cells, the 
MCF-7 and SK-MEL-2 cell lines also had negligible expression of the AM receptor Calcrl 
(Ct values ~32, data not shown). Therefore, AM is stimulating the LECs, rather than the 
tumor cells, to promote TEM.
Lymphatic endothelial cells form functional gap junctions upon AM treatment.
To assess whether gap junction formation is enhanced by AM treatment we performed a 
scrape loading dye transfer assay using the gap junction permeable dye Lucifer Yellow 
(LY). Treatment of LECs with 10nM hAM for 30 minutes resulted in a dramatic spread (3-
fold increase) of LY between the cells indicative of gap junction coupling (Figure 2). 
Importantly, this dye transfer was abrogated by pretreatment with the AM inhibitor AM22-52 
confirming that this was an AM-mediated effect. Furthermore, to verify that the spread of 
LY dye was through gap junctions rather than nonspecific dye transmission, we treated cells 
with the gap junction inhibitor carbenoxolone (CBX) 28 and subsequently detected no 
transfer of dye to adjacent cells (Figure 2). Taken together, these results suggest that AM 
treatment enhances gap junction mediated intercellular communication in LECs.
Connexins assemble to form gap junctions upon AM treatment.
We assessed the expression of connexins 37, 43, and 47 (Cx37, Cx43, Cx47) given their 
importance in lymphatic vascular development 11. Using real-time qPCR, we found that 
10nM hAM treatment of LECs caused an increase in GJA1, a decrease in GJA4, and no 
change in expression of GJC2 (Figure 3A-C). These dynamic changes in mRNA transcript 
were verified by western blot analysis of AM-treated LECs (Figure 3D,E). Using 
immunofluorescence analysis, we found that vehicle treated LECs displayed punctate Cx43 
staining throughout the cytoplasm with only minimal localization to the cell membranes 
(Figure 3F). By contrast, LECs treated for 15 minutes with 10nM hAM had Cx43 localized 
to regions of cell-cell contacts (Figure 3F). Analysis of Cx37 and Cx47 revealed no changes 
in localization upon hAM treatment (Figure 3G,H). The striking AM-induced membrane 
localization of Cx43 was prevented by treatment with the AM inhibitor AM22-52 (Figure 
3F). Interestingly, LECs pretreated with the GJ inhibitor CBX before addition of hAM still 
had localization of Cx43 to regions of cell-cell contact (Figure 3F). This suggests that gap 
junction coupling itself is not required for AM-induced Cx43 membrane localization. 
Collectively, these data show that stimulation of LECs with AM causes an upregulation of 
Cx43 expression and changes its sub-cellular localization to areas of cell-cell contact.
AM-overexpressing tumors have increased expression of Cx43 in lymphatic vessels
Studies have reported that levels of Cx43 mRNA or protein are dynamically regulated and 
for example, are elevated in estrogen stimulated endometrium 29 and metastatic 
tissue 22-24, 30. To determine if AM can similarly modulate Cx43 expression in vivo, we 
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subcutaneously injected mice with 1x106 AM-dosed LLC cells and harvested tumors after 
14 days 27. Lymphatic vessels were identified by LYVE1 staining, and interestingly, in the 
presence of high tumor derived AM (AM OExp), integrated density analysis revealed that 
the lymphatic vessels had increased expression of Cx43 (Figure 4). Furthermore, tumors 
expressing low levels of AM had only minimal Cx43 staining in the lymphatic vessels 
(Figure 4). These data demonstrate that in vivo tumor lymphatic vasculature responded to 
high levels of tumor-derived AM by upregulating Cx43 expression.
AM promotes heterocellular GJIC and blockade of this communication prevents TEM.
To address whether AM has the ability to promote heterocellular gap junction formation we 
performed a dye transfer assay. LLC tumor (donor) cells were loaded with the gap junction 
permeable dye Calcein while the LECs (acceptor) were loaded with the gap junction 
impermeable dye DiI. After a 3 hour co-culture, we observed almost 80% of hAM treated 
LECs (acceptor) were Calcein positive (Figure 5). Treatment with the gap junction inhibitor 
CBX completely blocked any transfer of Calcein from the tumor cells to LECs and 
confirmed that functional gap junction channels were responsible for the observed dye 
transfer. Next, we wanted to determine the functional consequences of this AM-induced 
heterotypic cellular communication and we hypothesized that GJIC may be necessary for the 
AM-induced TEM observed in Figure 2. Consistent with these results, we found that AM 
promoted the TEM of CTG- labeled tumor cells and intriguingly, CBX prevented the ability 
of tumor cells to migrate through an LEC monolayer (Figure 5B). These findings 
demonstrate that AM induced formation of functional gap junctions between tumor cells and 
LECs is necessary for tumor cell migration through an LEC monolayer.
AM-induced GJIC causes β-catenin nuclear translocation.
AM was recently identified as a Wnt/β-catenin target 31 and we examined whether this 
pathway was implicated in the TEM process by assessing β-catenin localization in LECs 
after treatment with hAM. In contrast to the jagged staining pattern observed at cell-cell 
contacts in control cells, 10nM hAM treatment caused a more linear arrangement of β-
catenin (Figure 6A). Given that β-catenin is part of a complex at the endothelial junction, 
this finding is consistent with the linearization observed in VE-cadherin staining upon AM 
treatment 32. Furthermore, treatment with AM induced nuclear localization of β-catenin in 
26% of hAM-treated LECs (Figure 6A,B). Importantly, the AM inhibitor AM22-52 prevented 
β-catenin translocation to the nucleus confirming that this translocation is triggered by AM 
signaling. The gap junction inhibitor CBX also failed to cause β-catenin accumulation at the 
nucleus, but interestingly, staining shows it was aligned at cell-cell contacts as seen in AM 
treated LECs (Figure 6A). This suggests that functional gap junctions are necessary for β-
catenin nuclear translocation which then leads to an increase in gene transcription of the 
downstream target C-MYC (Figure 6C). Our model summarizes how AM activates the 
lymphatic endothelium to promote tumor cell dissemination (Figure 6D). In the presence of 
AM, tumor cells exhibit increased adhesion to the LECs and transmigration through the 
monolayer requires functional gap junction mediated intercellular communication and 
subsequent β-catenin translocation to the nucleus.
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It has been speculated that tumor cells utilize similar mechanisms as immune cells to home 
to and transverse through the lymphatic endothelium. For example, gradients of CCR7 and 
CCL21 allow immune cells to chemoattract towards lymphatic vessels 33 and integrins have 
been shown to participate in the transit of immune cells across lymphatic endothelium under 
inflammatory conditions 34. In support of these findings, several groups have shown similar 
chemokine gradients contribute to tumor cell migration and invasion towards 
lymphatics 35-37. Furthermore, Garmy-Susini and colleagues identified integrin α4β1 as a 
marker of tumor lymphatic endothelium and the downstream signaling cascade it elicits 
promotes the adhesion and invasion of LECs 38. We find that AM promotes the adhesion of 
tumor cells to the lymphatic endothelium since blockade of AM signaling reduces the ability 
of tumor cells to adhere to the endothelium and establish functional heterocellular gap 
junction channels. It remains unclear whether the adhesion is directly mediated by integrins 
or perhaps through the gap junction protein, connexins which are expressed by both the 
tumor cells and the vasculature.
In addition to increased peri-tumoral lymphatics, enhanced lymphatic flow has also been 
reported to contribute to lymphatic metastasis 5, 6, 9. In a B16 melanoma tumor model, 
induction of lymph node lymphangiogenesis has been associated with a dramatic increase in 
lymph flow to the tumor-draining lymph node (LN) 9. We have previously shown that high 
levels of tumor-derived AM induces LN lymphangiogenesis 27 and literature suggests that 
the resultant enhanced flow could serve to promote initial tumor cell entry into the 
lymphatic vessels and then tumor cell transit into and through the draining LN. Intriguingly, 
disrupted lymph flow due altered gap junction function has been linked to mutations in 
GJC2 (encodes for the connexin 47 protein) 12. Similarly, conditional knockout mice for the 
AM receptor (Calclr) exhibit dysfunctional lymphatic flow and permeability 39. These 
results warrant further investigation to determine whether and how gap junctions facilitate 
lymph flow and importantly, how compromised lymph flow affects a pathological process 
like tumor metastasis.
The identification of mutations in the connexin gene family which cause alterations in gap 
junction mediated functions begs the question of whether this gene family can be exploited 
as a possible therapeutic target. The ability of the lymphatic vasculature to form 
heterocellular gap junctions with tumor cells to facilitate transendothelial migration has 
potentially important implications due to the phenomenon known as the bystander effect. 
The concept that a signal or molecule is transferred among neighboring cells to elicit a 
biological response has been used for example, as a treatment strategy for eradication of 
brain tumors 40. The commonly used approach involves retroviral mediated transfer of the 
herpes simplex virus thymidine kinase that sensitizes the transduced tumor or endothelial 
cells to the anti-viral ganciclovir to cause cell death. In a 9L brain tumor model using this 
strategy, researchers discovered a decrease in tumor vasculature and tumor regression 41. 
Intriguingly, evidence suggests that gap junction mediated intercellular communication is 
one mechanism that contributes to bystander cytotoxicity 42, 43. In fact, some have proposed 
to target connexins for gene therapy since their expression, localization at the plasma 
membrane, and assembly into functional gap junctions would improve the efficacy of 
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bystander effect 44. Our results clearly demonstrate that AM signaling promotes the 
organization of connexins into functional gap junctions to promote intercellular 
communication and subsequent TEM through a lymphatic monolayer. The development of 
therapies that rely upon functional coupling of cells and subsequent transfer of molecules 
among adjacent cells could provide a novel therapeutic strategy to disrupting or reducing the 
ability of tumor cells to escape through the lymphatics.
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The lymphatic vascular system contributes to the distant spread of tumor cells but the 
molecular mechanism of how this occurs is unclear. We provide evidence that the 
lymphangiogenic peptide adrenomedullin, found to be elevated in many tumors, 
promotes the adhesion and subsequent connexin mediated gap junction intercellular 
communication between tumor cells and lymphatic endothelial cells. This coupling or 
ability to communicate promotes transendothelial migration and we identify β-catenin 
nuclear translocation as a mediator of this process. This study provides novel insight into 
how the lymphatic endothelium communicates with tumor cells through gap junction 
channels to facilitate escape through the lymphatic vasculature.
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Adrenomedullin promotes the adhesion and transendothelial migration (TEM) of tumor cells 
to LECs. A. AM-dosed LLC cells were labeled with Cell Tracker Green (CTG) dye and 
incubated with a monolayer of LECs. After 15 minutes, non-adhered cells were aspirated 
and fluorescence of adhered cells was measured. B. Representative images of CTG-labeled 
tumor cells (black arrows) adhered to an LEC monolayer. Magnification: 10X. Scale bars: 
150µm. Phase contrast images are an optical zoom of the area surrounded by a white box. C. 
Graph depicts equal CTG labeling of the AM-dosed LLC cells. D. LECs were treated with 
vehicle or 1nM murine AM with or without a 30 minute pretreatment with the AM inhibitor 
AM22-52 (1µM) followed by addition of CTG-labeled LLC tumor cells for a 15 minute 
incubation. A,D. Fluorescence readings indicated an AM dose dependent increase in tumor 
cell adhesion to the LEC monolayer. Reduced AM levels through either RNAi depletion of 
Adm in tumor cells or pre-treatment with the AM inhibitor AM22-52 prevented the increased 
adhesion. E. A standard curve of CTG-labeled LLC and MCF-7 cells. F. CTG-labeled 
MCF-7 cells also exhibit an AM-induced increase in adhesion to LECs after 2 hour 
incubation. G. CTG-labeled AM-dosed LLC cells were seeded atop a confluent LEC 
monolayer and after a 6 hour co-culture, filters were removed from the transwell inserts. 
Image threshold analysis of 4 fields/ filter revealed that AM promoted TEM. H. Using a 
pharmacological approach, a confluent LEC monolayer was treated with vehicle or 1nM 
murine AM +/− AM22-52 followed by addition of CTG- labeled unmodified LLC cells 
similarly showed that AM promoted TEM. Analysis of 2 additional tumor cell lines, CTG-
labeled MCF-7 (I) and SK-MEL-2 (J) cells showed similar trends of AM enhanced TEM 
within 24 and 3 hours, respectively. G,H,I,J. Magnification: 10X. Scale bar: 100µm. The 
data shown are means ± SE and are representative of 3 independent experiments that yielded 
similar results.
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Adrenomedullin promotes the formation of gap junctions in LECs. Transfer of Lucifer 
yellow dye into neighboring LECs was determined after scrape-loading. Cells were 
pretreated with the AM inhibitor AM22-52 (1µM) or the gap junction inhibitor CBX (100µM) 
for 30 minutes, followed by treatment with 10nM human AM for 10 minutes. The percent of 
dye coupled cells was quantified by dividing the number of Lucifer yellow positive cells by 
the total number of cells in the field. Data represent means ± SE (n=3). Magnification: 10X. 
Scale bar: 100µm.
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Connexin expression and localization in response to adrenomedullin. A. Gene expression 
analysis revealed that treatment of LECs with 10nM human AM (4 hrs) caused an increase 
in GJA1 (A), a decrease in GJA4 (B), and no change in expression of GJC2 (C). D, E. 
Western blot analysis confirms these trends in expression following AM treatment (24 hrs) . 
F. LECs were pretreated with inhibitors (1µM AM22-52 or 100µM carbenoxolone) followed 
by a 15 minute treatment with 10nM hAM and then stained for Cx43. Immunofluorescence 
analysis revealed that AM and AM+CBX treatments caused a distinct linearization of Cx43 
at cell-cell contacts as compared to a more punctuate pattern in vehicle and AM inhibitor 
treatments. G, H. AM treatment of LECs failed to cause a change in localization of Cx37 
and Cx47. Magnification: 40X. Scale bar: 50µm.
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Mice were injected subcutaneously with AM-dosed LLC tumor cells (1x106) and after 14 
days tumors were collected. Tumors over-expressing AM (AM OExp) had increased 
expression of Cx43 within lymphatic vessels (LYVE1). Graph depicts integrated density 
analysis of Cx43 and reveals dose dependent expression of Cx43 with increased tumor AM 
expression. *One way ANOVA analysis: p=0.012. Magnification: 40X. Scale bars: 50µm.
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Heterocellular dye transfer and TEM are enhanced by adrenomedullin and require functional 
GJIC. A. LLC tumor cells (donor) loaded with 5µM calcein were co-cultured with mLECs 
(acceptor) that were labeled with 5µM DiI. mLECs were treated with vehicle (TC water), 
1nM mAM or mAM + CBX (100um) for 30 minutes prior to addition of calcein labeled 
LLC cells. After 3 hour co-culture, cells were fixed and analyzed for the number of tumor 
cells that transferred calcein to adjacent mLECs. Representative images are shown. 
Magnification: 40X. Scale bar: 50µm. B. Dye coupled cells were scored as positive if a 
calcein+ LLC tumor cell was in the same field and adjacent to a DiI+ and calcein+ mLEC. 
Dye coupling was expressed as a percent of the total number of tumor cells counted (~30-40 
cells/treatment). Graph depicts pooled data from 3 independent experiments. C. A confluent 
mLEC monolayer was treated with the gap junction inhibitor CBX (100µM) and murine AM 
(1nM) or vehicle for 30 minutes. CTG-labeled LLC cells were added to the monolayer and 
after a 6 hour co-culture, TEM was determined by fluorescent microscopy. The data shown 
are representative of 3 independent experiments that yielded similar results. Magnification: 
10X. Scale bar: 50µm.
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β-catenin nuclear translocation is promoted by adrenomedullin and is dependent on GJIC. A. 
Treatment of LECs with 10nM human AM caused an alignment of β-catenin at the 
membrane along with its nuclear translocation. These changes were prevented by 
pretreatment with AM inhibitor AM22-52 (1µM). The gap junction inhibitor CBX (100µM) 
prevented β-catenin nuclear translocation indicating that GJIC is necessary for its 
translocation. Magnification: 40X. Scale bar: 50µm. B. Quantification showing the 
percentage of cells with β-catenin nuclear translocation relative to the total number of cells 
in the field. 80-120 cells were analyzed for each treatment from 3 independent experiments 
and expressed as means ± SE. C. RNA isolated from LECs treated with vehicle or 10nM 
human AM (4hrs) was analyzed by qPCR for expression of C-MYC. D. The model depicts 
how high tumor-derived AM promotes increased tumor cell adhesion to LECs, connexin-
mediated GJIC, β-catenin nuclear translocation and subsequent gene transcription to 
facilitate transendothelial migration.
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